Molecular Genetic Study of Mayer-Rokitansky-Kuster-Hauser Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

410 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-31

Study Completion Date

2031-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to understand the molecular mechanisms leading to Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), the research team has to identify molecular bases of this anomaly.

Toward this goal, the research team would like to include in the study patients with MRKH syndrome, as well as their healthy relatives, in order to perform genetic analyses, especially whole exome sequencing.

This study has been set up in order to collect biological samples from patients with MRKH and their relatives.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Analysis of Uncommon Disease Presentations in Non-US Populations

NCT06595940

Undiagnosed Diseases Rare Diseases

RECRUITING

Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing

NCT06749366

Enchondromatosis

RECRUITING

Primary Premature Ejaculation Genetics

NCT02109302

Premature Ejaculation

COMPLETED NA

Method of Genetic Analysis in Genodermatoses

NCT03873285

Genodermatosis Rare Genetic Disease With Cutaneous Expression

UNKNOWN NA

Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases

NCT07075107

Rare Genetic Disease

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The MRKH is a congenital and rare malformation characterised by the absence of the uterus and of 2/3 of the vagina. The incidence is 1 in 4500 female children (46,XX) and a genetic component has been identified.

In order to understand the molecular mechanisms leading to this disease, the research team has to identify the genetic abnormalities.

This study will be led by the research team of the Imagine Institute and the clinical teams associated with the Reference Center for Rare Diseases PGR (Rare Gynecologic Diseases). Both groups are based on the Necker Hospital campus, and already closely collaborate on research into MRKH syndrome.

This collaboration will allow to :

i) collect biological samples from the propositus and their relatives,

ii) have a medical expertise.

The clinicians involved in the study will recruit patients, whose participation will involve providing a biological sample, ie, a blood sample and/or uterine tissue collected during surgical ablation, in the event that surgery is performed during clinical follow-up of the patients. No specific intervention will be planned for the purposes of this study.

In order to perform genetic analysis on trios, the healthy relatives of the patients (parents, brothers, sisters) will also be included. Blood samples will be taken once for healthy relatives.

Genetic analysis, especially whole exome sequencing, will be performed on blood samples by the research team of Imagine Institute.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mayer Rokitansky Kuster Hauser Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with MRKH syndrome

Biological samples for patients.

Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study.

Biological samples for patients

Intervention Type GENETIC

Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)

Healthy relatives

Biological samples for healthy relatives.

Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)

Biological samples for healthy relatives

Intervention Type GENETIC

Blood samples.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological samples for patients

Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)

Intervention Type GENETIC

Biological samples for healthy relatives

Blood samples.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with MRKH syndrome OR healthy relative of patient included
* Having signed the Informed consent form (or parents in case of patient under 18 years)

Exclusion Criteria

* Refusal to participate in genetic analyses
* Participation in a therapeutical clinical study in the 30 days prior to inclusion in the present study.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes